Correlation Between Body Mass Index and Blood Pressure with Severity of Psoriasis Vulgaris
Keywords:
psoriasis vulgaris, PASI, body mass index, blood pressureAbstract
Background: The immune system has a mediating role in psoriasis vulgaris, a skin illness characterized by persistent inflammation that flares up at irregular intervals and is frequently associated with obesity and hypertension. The prevalence of psoriasis vulgaris, hypertension, and obesity, are all recognized to be implicated in the same pathophysiological route, although the specific method through which the disease develops is yet unknown. Objective: To determine whether there is a correlation between psoriasis vulgaris severity and BMI and blood pressure. Methods: This was a retrospective study. Medical records of individuals with psoriasis vulgaris were collected from 2018 to 2020. The psoriasis area and severity index were used to assess the severity of psoriasis vulgaris. Results: A total of 181 patients of psoriasis vulgaris were enrolled. The number of female patients was more than male patients with 92 (50.8%) patients. Severe psoriasis vulgaris a severe degree within 121 (66.9%) patients. Psoriasis was corelated with body mass index and using the Spearman correlation p=0.002 with r=0.233, while the correlation between blood pressure and psoriasis vulgaris severity had p<0.001 with r=0.262. Conclusion: Body mass index and blood pressure are weakly correlated with the severity of psoriasis vulgaris.References
Gudjonsson JE, Elder JT. Psoriasis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al, editors. Fitzpatrick’s Derma-tology 9th Edition. 9th Editio. McGraw-Hill; 2019. p. 457–97.
Harden JL, Krueger JG, Bowcock AM. The immu-nogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015;64:66–73.
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: Sys-tematic analysis and modelling study. The BMJ. 2020:369.
de Oliveira M de FSP, Rocha B de O, Duarte GV. Psoriasis: Classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):09–20.
Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS, et al. Psoriasis and comorbid diseases: Epidemiology. J Am Acad Dermatol. 2017;76(3):377–90.
Ad??en E, Erduran F, Uzun S, Gürer MA. Prevalence of smoking, alcohol consumption and metabolic syndrome in patients with psoriasis. An Bras Dermatol. 2018;93(2):205–11.
Duarte GV, Oliveira M de FSP, Cardoso TM, Follador I, Silva TS, Cavalheiro CMA, et al. Association between obesity measured by different parameters and severity of psoriasis. Int J Der-matol. 2013;52(2):177–81.
Salihbegovic EM, Hadzigrahic N, Suljagic E, Kurtalic N, Sadic S, Zejcirovic A, et al. Psoriasis and high blood pressure. Med Arch. 2015;69(1):13–5.
Takeshita J, Wang S, Shin DB, Mehta NN, Kimmel SE, Margolis DJ, et al. Effect of psoriasis severity on hypertension control a population-based study in the United Kingdom. JAMA Dermatol. 2015;151(2): 161–9.
Bardazzi F, Balestri R, Baldi E, Antonucci A, De Tommaso S, Patrizi A. Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy. Dermatol Ther. 2010;23:S14–9.
Naito R, Imafuku S. Distinguishing features of body mass index and psoriasis in men and women in Japan: A hospital?based case–control study. J Dermatol. 2016;43(12):1406–11.
Phan C, Sigal ML, Lhafa M, Barthélémy H, Maccari F, Estève E, et al. Metabolic comorbidities and hypertension in psoriasis patients in France. Comparisons with French national databases. Ann Dermatol Venereol. 2016;143(4):264–74.
Wong Y, Nakamizo S, Tan K, Kabashima K. An update on the role of adipose tissues in psoriasis. Front Immunol. 2019;10:455506.
Jensen P, Skov L. Psoriasis and obesity. Derma-tology. 2017;232(6):633–9.
Kim H, Han K, Song S, Lee J. Hypertension and risk of psoriasis incidence: An 11-year nationwide population-based cohort study. PLoS One. 2018; 13(8):e0202854.
Rosa D, Machado R, Matias F, Cedrim S, Noronha F, Gaburri D, et al. Influence of severity of the cutaneous manifestations and age on the preva-lence of several cardiovascular risk factors in pati-ents with psoriasis. Journal of the European Academy of Dermatology and Venereology. 2012; 26(3):348–53.
Jacobi A, Kupke C, Behzad M, Hertl M. Comor-bidities, metabolic risk profile and health?related quality of life in German patients with plaque?type psoriasis: a cross?sectional prospective study. Int J Dermatol. 2013;52(9):1081–7.
Azfar R, Gelfand J. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol. 2008;20(4):416–22.
Cheng H, Li Y, Zuo X, Tang H, Tang X, Gao J, et al. Identification of a missense variant in LNPEP that confers psoriasis risk. Journal of Investigative Dermatology. 2014;134(2):359–65.
Armesto S, Coto?Segura P, Osuna C, Camblor P, Santos?Juanes J. Psoriasis and hypertension: a case?control study. Journal of the European Academy of Dermatology and Venereology. 2012;26(6):785–8.
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):1–14.
